MicroRNA-141 inhibits vascular smooth muscle cell proliferation through targeting PAPP-A

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 11, 2015, Pages 14401-14408

  Zhang, Yudong ^a   Chen, Bainan ^a   Ming, Liu ^a   Qin, Hongsong ^a   Zheng, Liu ^a   Yue, Zhang ^a   Cheng, Zhixin ^a   Wang, Yannan ^a   Zhang, Dawei ^a   Liu, Chunmei ^a   Bin, Wang ^a   Hao, Qingzhi ^a   Song, Fuchen ^a   Ji, Bo ^a  

^a AFFILIATED HOSPITAL OF SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Atherosclerosis; MiR 141; Ox LDL; Proliferation; Vascular smooth muscle cells

Indexed keywords

LOW DENSITY LIPOPROTEIN; MICRORNA; MIRN141 MICRORNA, HUMAN; OXIDIZED LOW DENSITY LIPOPROTEIN; PAPPA1 PROTEIN, HUMAN; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ATHEROSCLEROSIS; CELL CULTURE; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CELL; TIME FACTOR; VASCULAR SMOOTH MUSCLE;

ATHEROSCLEROSIS; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HUMANS; LIPOPROTEINS, LDL; MICRORNAS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 85013498098     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Aghabozorg Afjeh SS and Ghaderian SM. The role of microRNAs in cardiovascular disease. Int J Mol Cell Med 2013; 2: 50-57.
2. Chen KC and Hank Juo SH. MicroRNAs in atherosclerosis. Kaohsiung J Med Sci 2012; 28: 631-640.
3. Sun Y, Chen D, Cao L, Zhang R, Zhou J, Chen H, Li Y, Li M, Cao J and Wang Z. MiR-490-3p modulates the proliferation of vascular smooth muscle cells induced by ox-LDL through targeting PAPP-A. Cardiovasc Res 2013; 100: 272-279.
4. Pirillo A, Norata GD and Catapano AL. LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm 2013; 2013: 152786.
5. Liang W, Gao B, Fu P, Xu S, Qian Y and Fu Q. The miRNAs in the pathgenesis of osteosarcoma. Front Biosci (Landmark Ed) 2013; 18: 788-794.
6. Banaudha KK and Verma M. The role of microRNAs in the management of liver cancer. Methods Mol Biol 2012; 863: 241-251.
7. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, Yoshida K, Sasaki H, Nomura S, Seto Y, Kaminishi M, Calin GA and Croce CM. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 2010; 11: 136-146.
8. Han M, Toli J and Abdellatif M. MicroRNAs in the cardiovascular system. Curr Opin Cardiol 2011; 26: 181-189.
9. Li J, Zhao L, He X, Yang T and Yang K. MiR-21 inhibits c-Ski signaling to promote the proliferation of rat vascular smooth muscle cells. Cell Signal 2014; 26: 724-729.
10. Mackenzie NC, Staines KA, Zhu D, Genever P and Macrae VE. miRNA-221 and miRNA-222 synergistically function to promote vascular calcification. Cell Biochem Funct 2014; 32: 209-216.
11. Liu X, Cheng Y, Zhang S, Lin Y, Yang J and Zhang C. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res 2009; 104: 476-487.
12. Wang YS, Li SH, Guo J, Mihic A, Wu J, Sun L, Davis K, Weisel RD and Li RK. Role of miR-145 in cardiac myofibroblast differentiation. J Mol Cell Cardiol 2014; 66: 94-105.
13. Boucher JM, Peterson SM, Urs S, Zhang C and Liaw L. The miR-143/145 cluster is a novel transcriptional target of Jagged-1/Notch signaling in vascular smooth muscle cells. J Biol Chem 2011; 286: 28312-28321.
14. Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta N, Steer BM, Ingram AJ, Gupta M, Al-Omran M, Teoh H, Marsden PA and Verma S. MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation 2012; 126: S81-90.
15. Zhang C. MicroRNA-145 in vascular smooth muscle cell biology: a new therapeutic target for vascular disease. Cell Cycle 2009; 8: 3469-3473.
16. Elia L, Quintavalle M, Zhang J, Contu R, Cossu L, Latronico MV, Peterson KL, IndolfiC, Catalucci D, Chen J, Courtneidge SA and Condorelli G. The knockout of miR-143 and-145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ 2009; 16: 1590-1598.
17. Quintavalle M, Elia L, Condorelli G and Courtneidge SA. MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro. J Cell Biol 2010; 189: 13-22.
18. Ding Z, Wang X, Schnackenberg L, Khaidakov M, Liu S, Singla S, Dai Y and Mehta JL. Regulation of autophagy and apoptosis in response to ox-LDL in vascular smooth muscle cells, and the modulatory effects of the microRNA hsa-let-7 g. Int J Cardiol 2013; 168: 1378-1385.
19. Zhang Y, Chen N, Zhang J and Tong Y. Hsa-let-7g miRNA targets caspase-3 and inhibits the apoptosis induced by ox-LDL in endothelial cells. Int J Mol Sci 2013; 14: 22708-22720.
20. Qin B, Xiao B, Liang D, Li Y, Jiang T and Yang H. MicroRNA let-7c inhibits Bcl-xl expression and regulates ox-LDL-induced endothelial apoptosis. BMB Rep 2012; 45: 464-469.
21. Maiolino G, Rossitto G, Caielli P, Bisogni V, Rossi GP and Calo LA. The role of oxidized lowdensity lipoproteins in atherosclerosis: the myths and the facts. Mediators Inflamm 2013; 2013: 714653.
22. Zhang Y, Wang Y, Wang X, Eisner GM, Asico LD, Jose PA and Zeng C. Insulin promotes vascular smooth muscle cell proliferation via microRNA-208-mediated downregulation of p21. J Hypertens 2011; 29: 1560-1568.
23. Khaidakov M and Mehta JL. Do atherosclerosis and obesity-associated susceptibility to cancer share causative link to oxLDL and LOX-1? Cardiovasc Drugs Ther 2011; 25: 477-487.
24. Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu X, Xiao P, Shi H, Wang R, Chen L, Chen S, Du Q, Yang H and Zhang X. miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression. Clin Cancer Res 2014; 20: 2617-2630.
25. Qiu W and Kassem M. miR-141-3p inhibits human stromal (mesenchymal) stem cell proliferation and differentiation. Biochim Biophys Acta 2014; 1843: 2114-2121.
26. Consuegra-Sanchez L, Fredericks S and Kaski JC. Pregnancy-associated plasma protein-A (PAPP-A) and cardiovascular risk. Atherosclerosis 2009; 203: 346-352.
27. Consuegra-Sanchez L, Fredericks S and Kaski JC. Pregnancy-associated plasma protein A: Has this biomarker crossed the boundary from research to clinical practice? Drug News Perspect 2009; 22: 341-348.
28. Gruber HE, Hoelscher G, Ingram JA and Hanley EN Jr. Immunolocalization and biochemical evidence of pregnancy-associated plasma protein A in the intervertebral disc. Spine (Phila Pa 1976) 2008; 33: E447-454.
29. Thorn EM and Khan IA. Pregnancy-associated plasma protein-A: an emerging cardiac biomarker. Int J Cardiol 2007; 117: 370-372.
30. Resch ZT, Oxvig C, Bale LK and Conover CA. Stress-activated signaling pathways mediate the stimulation of pregnancy-associated plasma protein-A expression in cultured human fibroblasts. Endocrinology 2006; 147: 885-890.
31. Bayes-Genis A, Schwartz RS, Lewis DA, Overgaard MT, Christiansen M, Oxvig C, Ashai K, Holmes DR Jr and Conover CA. Insulin-like growth factor binding protein-4 protease produced by smooth muscle cells increases in the coronary artery after angioplasty. Arterioscler Thromb Vasc Biol 2001; 21: 335-341.
32. Liu ZY, Zhang JY, Sun TW, Zhang YJ, Zhang L and Wang LX. Levels of pregnancy-associated plasma protein A in patients with coronary artery disease. Clin Invest Med 2008; 31: E85-89.
33. You L, Li L, Zhang F, Xu Q and Ren J. A pilot study of the clinical relevance of the relationship between the serum level of pregnancyassociated plasma protein A and the degree of acute coronary syndrome. J Int Med Res 2010; 38: 625-632.